On July 26, 2026, global AI chip giant NVIDIA announced in Shenzhen a strategic partnership with China's leading gene sequencing company BGI to jointly develop a drug target discovery platform based on large AI models. This marks NVIDIA's first deep involvement in the full drug R&D process in China, signaling that AI drug discovery has entered a large-scale implementation phase.
Partnership Details: Large AI Models Disrupt Traditional Drug Development
Under the agreement, NVIDIA will provide its newly released BioNeMo AI framework and CUDA-accelerated computing power, while BGI contributes its world's largest gene database and drug molecule library. The jointly developed platform aims to shorten the traditional drug discovery cycle from 3-5 years to 6-12 months, reducing R&D costs by over 70%.
Specifically, the platform will use large models to learn the relationship between known protein structures and drug activity, automatically generating candidate molecules and predicting their toxicity and metabolic pathways. The initial key focus areas are complex diseases such as Alzheimer's disease and non-small cell lung cancer.
Industry Background: AI Drug Discovery Financing Hits Record Highs
In recent years, AI technology has been profoundly reshaping the pharmaceutical industry. According to the 2026 Global AI Drug Discovery White Paper, global financing in the AI drug discovery sector reached $3.8 billion in the first half of 2026, up 45% year-on-year, with the share of China-related companies jumping from 12% in 2024 to 29%.
On the policy front, China's National Medical Products Administration (NMPA) released the Technical Guidelines for AI-Assisted Drug R&D in March 2026, providing for the first time review standards for AI applications and clarifying that "AI computing results can serve as important supporting materials for new drug clinical trial applications." This policy directly catalyzed deep collaborations between tech giants like NVIDIA and pharmaceutical companies.
Technical Approach: Integration of Generative AI and Physical Simulation
Behind the Xifeng Bioweath platform in this partnership lies the integration of two technical routes:
- Generative diffusion models: learning from millions of known compound structures to generate new molecular scaffolds that meet drug efficacy constraints
- Molecular dynamics simulations: using NVIDIA GPUs to simulate the binding stability of molecules and target proteins, screening high-activity candidates
Kimberly Powell, Vice President of NVIDIA Healthcare, stated at the press conference: "We are no longer just providing computing power; we are co-building an end-to-end AI pipeline from target discovery to preclinical research with pharmaceutical companies. BGI's genetic data is a scarce resource for training high-quality models."
Industry Impact: Disrupting Traditional CRO and Biotech Ecosystems
This partnership will impact the traditional contract research organization (CRO) business model. Traditional CROs rely on manual experiments to accumulate data, while AI-driven platforms can evaluate tens of thousands of molecules simultaneously, offering overwhelming efficiency. Shares of domestic CRO giant WuXi AppTec fell 4.5% on the same day, reflecting market concerns that its core business could be displaced by AI.
Meanwhile, biotech startups benefit from AI tools that lower R&D barriers. Li Ming, CEO of AI drug discovery startup Jingrui Technology, said: "Previously, we needed large amounts of capital to set up dry and wet lab equipment. Now, by calling cloud-based AI models via APIs, we can complete virtual screening in three days that used to take three months."
Investment Opportunities: Focus on Computing Power, Data, and Validation Capabilities
For investors, the AI drug discovery track requires attention to three core elements:
- Computing power infrastructure: AI training requires large quantities of GPUs, benefiting NVIDIA, AMD, and domestic computing power providers
- High-quality data moats: Companies with large-scale labeled data like BGI and WuXi AppTec have first-mover advantages
- Clinical validation capability: After AI proposes candidate molecules, real clinical trials are still needed; companies with clinical resource integration capabilities can realize commercial value
Wall Street investment bank Jefferies' research report indicates that the global AI drug discovery market will grow from $1.4 billion in 2025 to $14.7 billion by 2030, with a CAGR of over 60%. Chinese companies enjoy unique advantages in data volume and policy support, and the bank recommends overweighting AI+healthcare.
Challenges and Outlook
Nevertheless, AI drug discovery still faces interpretability bottlenecks and data quality issues. Currently, most AI models rely on public datasets, and private data sharing mechanisms are not yet mature. Additionally, AI predictions need to be combined with closed-loop lab validation to avoid investing in ineffective molecules due to "AI hallucinations."
Industry experts believe that the partnership between NVIDIA and BGI sets a benchmark for the industry, but a true breakthrough still awaits the approval of the first AI-discovered drug. Yin Ye, CEO of BGI, stated: "We expect to submit the first clinical trial application for an AI-assisted discovered drug before the end of 2027. That will be a historic moment for Chinese AI drug discovery."
At the intersection of AI and biomedicine, a revolution in efficiency is accelerating. For investors tracking AI industry trends, this is both a track full of imagination and a battlefield that tests technical judgment and patience.
